Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease.

Xavier RoblinStéphane NanceyKonstantinos PapamichaelGérard DuruMathurin FlamandSandy KwiatekAdam CheifetzNicole FabienMathilde BarrauStéphane Paul

Published in: Journal of Crohn's & colitis (2023)

Higher SC-IFX concentrations are associated with higher rates of favorable therapeutic outcomes in IBD patients. Serum SC-IFX concentrations higher than 20µg/mL were significantly associated with deep remission.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
ejection fraction
disease activity
type diabetes
rheumatoid arthritis
systemic lupus erythematosus
patient reported outcomes
weight loss
insulin resistance